Ditta Zobor1, Annette Werner1, Franco Stanzial2, Francesco Benedicenti2, Günther Rudolph3, Ulrich Kellner4, Christian Hamel5, Sten Andréasson6, Gergely Zobor1, Torsten Strasser1, Bernd Wissinger1, Susanne Kohl1, Eberhart Zrenner7. 1. Center for Ophthalmology, University of Tübingen, Tübingen, Germany. 2. Department of Pediatrics, Genetic Counseling Service, Hospital of Bolzano, Bolzano, Italy. 3. Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany. 4. Rare Retinal Disease Center, AugenZentrum Siegburg, Siegburg, Germany. 5. Institute of Neurosciences of Montpellier, Hôpital Saint Eloi, Montpellier, France. 6. Department of Ophthalmology, Lund University, Lund, Sweden. 7. Center for Ophthalmology, University of Tübingen, Tübingen, Germany 7Werner Reichardt Center for Integrative Neuroscience, University of Tübingen, Tübingen, Germany.
Abstract
Purpose: The purpose of this study was to clinically characterize patients with CNGA3-linked achromatopsia (CNGA3-ACHM) in preparation of a gene therapy trial. Methods: Thirty-six patients (age 7-56 years) with complete (cACHM) or incomplete (iACHM) CNGA3-ACHM were examined, including detailed psychophysical tests, extended electrophysiology, and assessment of morphology by fundus autofluorescence and spectral-domain optical coherence tomography (SD-OCT). Results: Mean best-corrected visual acuity was 0.78 ± 0.14 logMAR. Color vision tests were consistent with a rod-dominated function in every cACHM patient. Microperimetry indicated an overall lowered retinal sensitivity within 20° of visual field. In electroretinography (ERG), photopic responses were nondetectable in cACHM patients, but residual cone responses were observed in the iACHM patients. Scotopic responses were altered referring to anomalies of photoreceptor and postreceptor signaling, whereas in voltage versus intensity functions, Vmax was significantly below normal values (P < 0.05). In contrast, slope (n) and semisaturation intensity (K) were found to be within normal limits. Spectral-domain OCT examination showed no specific changes in 14.7%, disruption of the ellipsoid zone (EZ) at the fovea in 38.2%, absent EZ in 17.7%, a hyporeflective zone in 20.5%, and outer retinal atrophy in 8.9% of all cases and foveal hypoplasia in 29 patients (85%). No correlation of retinal morphology with visual function or with a specific genotype was found. The severity of morphologic and functional changes lacked a robust association with age. Conclusions: Our extended investigations prove that even among such a genetically homogenous group of patients, no specific correlations regarding function and morphology severity and age can be observed. Therefore, the therapeutic window seems to be wider than previously indicated.
Purpose: The purpose of this study was to clinically characterize patients with CNGA3-linked achromatopsia (CNGA3-ACHM) in preparation of a gene therapy trial. Methods: Thirty-six patients (age 7-56 years) with complete (cACHM) or incomplete (iACHM) CNGA3-ACHM were examined, including detailed psychophysical tests, extended electrophysiology, and assessment of morphology by fundus autofluorescence and spectral-domain optical coherence tomography (SD-OCT). Results: Mean best-corrected visual acuity was 0.78 ± 0.14 logMAR. Color vision tests were consistent with a rod-dominated function in every cACHM patient. Microperimetry indicated an overall lowered retinal sensitivity within 20° of visual field. In electroretinography (ERG), photopic responses were nondetectable in cACHM patients, but residual cone responses were observed in the iACHM patients. Scotopic responses were altered referring to anomalies of photoreceptor and postreceptor signaling, whereas in voltage versus intensity functions, Vmax was significantly below normal values (P < 0.05). In contrast, slope (n) and semisaturation intensity (K) were found to be within normal limits. Spectral-domain OCT examination showed no specific changes in 14.7%, disruption of the ellipsoid zone (EZ) at the fovea in 38.2%, absent EZ in 17.7%, a hyporeflective zone in 20.5%, and outer retinal atrophy in 8.9% of all cases and foveal hypoplasia in 29 patients (85%). No correlation of retinal morphology with visual function or with a specific genotype was found. The severity of morphologic and functional changes lacked a robust association with age. Conclusions: Our extended investigations prove that even among such a genetically homogenous group of patients, no specific correlations regarding function and morphology severity and age can be observed. Therefore, the therapeutic window seems to be wider than previously indicated.
Authors: Katie M Litts; Michalis Georgiou; Christopher S Langlo; Emily J Patterson; Rebecca R Mastey; Angelos Kalitzeos; Rachel E Linderman; Byron L Lam; Gerald A Fishman; Mark E Pennesi; Christine N Kay; William W Hauswirth; Michel Michaelides; Joseph Carroll Journal: Curr Eye Res Date: 2020-03-13 Impact factor: 2.424
Authors: Margaret R Strampe; Alison L Huckenpahler; Brian P Higgins; Sergey Tarima; Alexis Visotcky; Kimberly E Stepien; Christine N Kay; Joseph Carroll Journal: Transl Vis Sci Technol Date: 2018-06-04 Impact factor: 3.283
Authors: Rebecca R Mastey; Mina Gaffney; Katie M Litts; Christopher S Langlo; Emily J Patterson; Margaret R Strampe; Angelos Kalitzeos; Michel Michaelides; Joseph Carroll Journal: Transl Vis Sci Technol Date: 2019-10-02 Impact factor: 3.283
Authors: Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson Journal: Prog Retin Eye Res Date: 2019-12-30 Impact factor: 21.198
Authors: Katie M Litts; Erica N Woertz; Niamh Wynne; Brian P Brooks; Alicia Chacon; Thomas B Connor; Deborah Costakos; Alina Dumitrescu; Arlene V Drack; Gerald A Fishman; William W Hauswirth; Christine N Kay; Byron L Lam; Michel Michaelides; Mark E Pennesi; Kimberly E Stepien; Sasha Strul; C Gail Summers; Joseph Carroll Journal: Transl Vis Sci Technol Date: 2021-05-03 Impact factor: 3.048